Logo Image
News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademyShortsSponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Events
Webcasts
Event Calendar

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Events
  • Subscribe
  • Event Calendar
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
Clinical Operations & Strategy|
Patient Participation
Advertisement
|Articles|November 14, 2018

Ways to Reduce Sample Size In Clinical Trials

Author(s)Company Press Release
Advertisement

To Learn more, visit Statsols.com.

Advertisement

Related Content

Advertisement

Selective Safety Data Collection and the Case for Simpler Trials: Q&A with Rob DiCicco, TransCelerate Biopharma

ByRob DiCicco,Andy Studna, Senior Editor
July 14th 2026

The Biggest Adoption Challenges in Moving to Portfolio-Level Recruitment

ByGaynor Anders,Andy Studna, Senior Editor
July 14th 2026

ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy

ByAndy Studna, Senior Editor
July 14th 2026
© photon_photo - © photon_photo - stock.adobe.com

Before Burden Becomes Risk: Capturing Friction in Real Time

ByBrian S. McGowan, PhD, FACEHP,Kelly Ritch,Jason Riis, PhD
July 13th 2026

What Program-Level Recruitment Requires from Sponsors Operationally

ByGaynor Anders,Andy Studna, Senior Editor
July 13th 2026
Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

2

ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development

3

ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy

4

Before Burden Becomes Risk: Capturing Friction in Real Time

5

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us